Key result
Adiponectin may protect against diabetic retinopathy by reducing insulin resistance, oxidative stress, and inflammation.
Why the study?
A growing body of research indicates adiponectin plays a significant role in diabetic retinopathy, prompting exploration of its protective effects and potential therapeutic targets.
Adiponectin is a potential therapeutic target and predictive marker for diabetic retinopathy due to its anti-inflammatory, anti-oxidative, and vascular protective effects.
Answers are grounded in this paper and cite their sources.
Adiponectin merits study as biomarker and target in diabetic retinopathy; leaves open any practice change pending prospective trials.
Adiponectin, one of the most ubiquitous adipokines found in the blood, plays a major role in glucolipid metabolism and energy metabolism and regulation. In recent years, a growing body of research indicates that adiponectin also plays a significant role in diabetic retinopathy. In the present review, we specifically address the protective effects of adiponectin on the development and progression of diabetic retinopathy through improvement in insulin resistance, alleviation of oxidative stress, limiting of inflammation, and prevention of vascular remodeling, with the aim to explore new potential approaches and targets for the prevention and treatment of diabetic retinopathy.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2023) conducted a review in Diabetic Retinopathy. Adiponectin was evaluated. Adiponectin may have a protective effect on the development and progression of diabetic retinopathy by improving insulin resistance, alleviating oxidative stress, and limiting inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: